|
市場調查報告書
癌生物標誌：改變癌管理方式的新工具
Cancer Biomarkers: New Tools for Transforming Cancer Management
|
本報告已在2011年12月21日停止出版。
新的癌生物標誌幾乎每星期會被報告出來，然而適用於判斷其妥當性的工具卻少之又少。
專門於醫療業界領域進行廣泛調查的美國專業調查公司Decision Resources Inc. (總公司：Massachusetts)，調查分析了有關癌生物標誌並有系統地出版了報告書 "Cancer Biomarkers: New Tools for Transforming Cancer Management"。
此報告書除了調查癌生物標誌開發動向與新興生物標誌，也整理了癌生物標誌企業概況與課題等。報告書之內容摘要如下所示。
摘要
概要
癌管理用生物標誌至今為止的使用
癌生物標誌開發動向
- 生物標誌發現
- 癌生物標誌臨床評價
- Ciphergen
- Miraculins
- Panacea Pharmaceuticals
- Biomarker Technologies
- 診斷產業加入
探知技術的進步
癌生物標誌應用
- 臨床實驗設計的變革
- 遺傳子因素
- 篩檢與癌的早期發現
- 診斷與預後診斷
- 治療與反應
- 復發
在各式各樣的癌之中所產生的新興生物標誌
- 膀胱癌
- 乳癌
- 結腸直腸癌
- 肺癌
- 胰臟癌
- 前列腺癌
- 腎細胞癌
癌生物標誌於臨床使用上的障璧
- 技術上的課題
- 集中管理資料庫的不足
- 經濟上的課題
- 管理監督
癌生物標誌企業現在的活動
- Biomarker Technologies
- Ciphergen
- Claros Diagnostics
- Epigenomics
- Exagen Diagnostics
- Genesis Genomics
- Health Discovery Corporation
- Ipsogen
- Matritech
- Miraculins
- Orion Genomics
- Phenomenome Discoveries
- Power3 Medical Products
- Upstream Biosciences
圖表
Abstract
Introduction
Although novel cancer biomarkers are reported on a weekly basis, only a
handful are actually translated into fully validated diagnostic tools. To
fully understand the process, we explore the current status of the cancer
biomarker fi eld, roadblocks that slow the development process, the cancer
biomarker pipeline, as well as the outlook for integrating cancer biomarkers
into clinical practice. We also profi le select companies that are actively
pursuing cancer biomarker discovery and development.
Get the Answers You Need to Shape Your Strategy
- Companies are utilizing cutting-edge technologies to develop, validate,
and implement cancer biomarkers for clinical use. What impediments still exist
to incorporating promising research into clinical practice? Which biomarkers
show the most promise for approval?
- Integrating cancer biomarkers into clinical practice is the goal for
development companies as well as clinicians. What are the economic challenges
to approval? How can regulatory oversight drive approval and adoption of new
technologies?
- No one company or agency has the necessary scope or expertise to drive the
discovery, development, and implementation of sensitive and specifi c
biomarkers. Which alliances show the greatest synergy in bringing valid
biomarkers to market? Which shared technologies are driving the most
encouraging development?
Scope
- Trends in Cancer Biomarker Development: Biomarker discovery and
validation, as well as the role of the diagnostics.
- Emerging Biomarkers in Select Cancers: Bladder, breast, colorectal,
lung, pancreatic, prostate, and renal cell.
- Profi les of Select Cancer Biomarker Companies: Biomarker
Technologies, Ciphergen, Claros Diagnostics, Epigenomics, Exagen Diagnostics,
Genesis Genomics, Health Discovery Corporation, Ipsogen, Matritech,
Miraculins, Orion Genomics, Phenomenone Discoveries, Power3 Medical Products,
Upstream Biosciences.
- Challenges: How strategic alliances and interdisciplinary
involvement will need to drive development and implementation of emerging
biomarker technologies.
Mentioned in This Spectrum Report
- Access Genetics
- Acrongenomics
- Advanced Magnetics
- Affymetrix
- Agendia
- Atairgin Technologies
- Applied Biosystems
- Arcturus Biosciences
- AstraZeneca
- AviaraDx
- Bayer
- Bayer HealthCare
- Baylor College of Medicine
- BioAlliance Pharma
- BioGenex Laboratories
- Biomarker Technologies
- bioMerieux
- Biomira Diagnostics
- Biosite
- Brigham and Women' s
- Hospital
- The Burnham Institute
- Cangen Biotechnologies
- Centocor
- Centre National de la
- Recherche Scientifi que
- Children' s Medical Center
- Ciphergen Biosystems
- Claros Diagnostics
- CMX Research
- Cornell Research Foundation
- Cytoclonal Pharamaceutics
- Cytyc Health
- Dade-Behring
- Dako
- DiaDexus
- DiagnoCure
- EDP Biotech
- Elan
- Emory University
- EntreMed
- Epigenomics
- Erasmus MC, University
- Medical Center Rotterdam
- Exagen Diagnostics
- Genaissance Pharmaceuticals
- Gene Fluidics
- GeneNews
- Genentech
- Genesis Genomics
- Genomic Health
- Genzyme
- Gerald P. Murphy Cancer
- Foundation
- Glycominds
- Health Discovery Corporation
- Henry M Jackson Foundation
- for the Advancement of
- Military Medicine
- Hycor Biomedical
- Immunicon
- InterGenetics
- Intracel
- Ipsogen
- Inverness Medical Innovations
- JTAT
- Johns Hopkins University
- Johnson & Johnson
- Loma Linda University
- Matritech
- Mayo Foundation for Medical
- Education and Research
- Medical College of Georgia
- Research Institute
- Millennium Pharmaceuticals
- Miraculins
- Mount Sinai Hospital
- Myriad Genetics
- Nanogen
- Nanospectra Biosciences
- Nanosphere
- Orion Genomics
- Ortho-Clinical Diagnostics
- Oxford Genome Sciences
- Panacea Pharmaceuticals
- Pfi zer
- Phenomenome Discoveries
- Polymedco
- Power3 Medical Products
- PrecisionMed
- Proteome Systems
- Quantum Dot
- Quest Diagnostics
- Qiagen
- Roche
- Shimadzu
- Sloan-Kettering Institute for
- Cancer Research
- Texas A&M University
- Thomas Jefferson University
- TriPath Imaging
- UB Institute for Lasers,
- Photonics, and Biophotonics
- University of Michigan
- University of Mississippi
- Medical Center
- University of New Mexico' s
- Science and Technology
- Corporation
- University of Pittsburgh
- University of Texas Systems
- Upstream Biosciences
- Urocor
- Ventana Medical System
- Vysis
- Wako Chemicals USA
Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Overview
- Traditional Use of Biomarkers in Cancer Management
- Trends in Cancer Biomarker Development
- Biomarker Discovery
- Clinical Validation of Cancer Biomarkers
- Ciphergen
- Miraculins
- Panacea Pharmaceuticals
- Biomarker Technologies
- Engagement of Diagnostics Industry
- Recent Advances in Detection Technologies
- Image-Based Biomarkers
- The "omics" Platforms
- Nanodiagnostics
- Applications of Cancer Biomarkers
- Transformation of Clinical Trial Design
- Genetic Predisposition
- Screening and Early Detection of Cancer
- Diagnosis and Prognosis
- Treatment Selection and Response
- Recurrence
- Emerging Biomarkers in Select Cancers
- Bladder Cancer
- Breast Cancer
- Colorectal Cancer
- Lung Cancer
- Pancreatic Cancer
- Prostate Cancer
- Renal Cell Carcinoma
- Roadblocks to Integrating Cancer Biomarkers into Clinical Practice
- Technical Challenges
- Lack of a Centralized Database
- Economic Challenges
- Regulatory Oversight
- Current Activities of Cancer Biomarker Companies
- Biomarker Technologies
- Ciphergen
- Claros Diagnostics
- Epigenomics
- Exagen Diagnostics
- Genesis Genomics
- Health Discovery Corporation
- Ipsogen
- Matritech
- Miraculins
- Orion Genomics
- Phenomenome Discoveries
- Power3 Medical Products
- Upstream Biosciences
Tables:
- 1. Sensitivities and Specifi cities of Select FDA-Approved Traditional
Cancer Biomarkers
- 2. FDA-Approved Cancer Biomarkers with Companion Diagnostic Tests
- 3. Select Cancer Biomarker Patent Filings
- 4. Select Issued Patents for Cancer Biomarkers in the United States
(2001-Present)
- 5. Select Nanodiagnostic Products
- 6. Available Tests for Genetic Predisposition to Cancer Development
- 7. Profi les of Companies Engaged in Cancer Biomarker Development
Figures:
- 1. Overall Five-Year Survival, by Stage
- 2. Potential Impact of Cancer Biomarkers in Drug Discovery and Drug
Development Processes
- 3. Applications of Biomarkers in Cancer Management
|
